Issue link: https://www.e-digitaleditions.com/i/1468049
34 Pharmaceutical Technology TRENDS IN MANUFACTURING 2022 eBOOK P h a r mTe c h . c o m Continuous Manufacturing for perfusion processing. Based on this develop- ment, we plan to demonstrate a proof-of-concept involving feedback control of glycosylation using our newly developed feeding strateg y. In col- laboration with other KTH scientists, analytical chemists, and microf luidics experts within the European Union project, iConsensus, we are also working on miniaturized measurements of the antibody charge variant and the quantification of the host cell proteins (HCPs). PAT of charge-vari- ant detection will be a precious tool to implement, since this quality attribute can also vary in the bioreactor. We are also looking at in-line sensors for the measurement of antibody titer, which will be helpful to further improve purification robust- ness by feedback control. Finally, HCP quanti- fication during the purification process can be instrumental for the optimization of the process, its robustness, and on-line performance monitor- ing of the equipment. PharmTech: What is the role of single-use tech- nologies in your process? Chotteau (AdBIOPRO): Single-use equipment has al- lowed us to quickly mount a completely new set- ting at pilot-scale of a complex system of upstream processing equipment connected to downstream processing equipment, including the seed bioreac- tor. This set-up has taken only a couple of days; stainless-steel equipment would have required a longer time and less f lexibility in the set-up. A real advantage is to be able to do whatever you want, in particular for the connections, and to also have the f lexibility to easily do modifications. Using stainless-steel equipment, all the modifica- tions would have to be somehow planned from the beginning, which is very difficult for an R&D experiment. All the tube connections are also rap- idly done with single-use equipment, while this is much slower and complex with stainless steel. Another feature is that the risk of contamination of the culture is almost none. Having run a so- phisticated perfusion culture in stainless-steel equipment at pilot-scale, I can tell you that this reduced risk is really important. PT Pharmaceutical Technology presents the Drug Solutions Podcast, where the editors chat with industry experts from across the pharmaceutical and biopharmaceutical supply chain. Join us as experts share insights into your biggest questions—from the technologies, to strategies, to regula- tions related to the development and manufacture of drug products. In this episode of the Drug Solutions Podcast, Feliza Mirasol, Pharmaceutical Technology's science editor, discusses technologies enabling biologic s and emerging therapies manufac turing and development with Barr y Holt z, PhD, chief scientif ic of f icer of Phylloceuticals, and Professor Yaakov Nahmias, founder and chief scientific officer, Tissue Dynamics and founder and president, Future Meat Technologies. Mirasol explores innovative approaches, such as plant-made pharmaceutical manufac turing technology and organ-on-a-chip technology, that have been successful in enabling the development and manufacturing scale-up of biologics as well as some emerging therapies. Mirasol also discusses industry challenges, including cost considerations and development timelines, with Barry Holtz, PhD, Chief Scientif ic Of f icer of Phylloceuticals, and Professor Yaakov Nahmias, founder and chief scientific of ficer, Tissue Dynamics and founder and president, Future Meat Technologies. Click HERE to listen to the podcast. Drug Solutions Podcast: Biologic Drug Development and Manufacturing